

Sanofi  
Form 6-K  
September 12, 2013

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

---

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER  
PURSUANT TO RULE 13a-16 OR 15d-16  
UNDER THE SECURITIES EXCHANGE ACT OF 1934**

---

**For the month of September 2013**

**Commission File Number: 001-31368**

**SANOFI**

(Translation of registrant's name into English)

**54, rue La Boétie, 75008 Paris, FRANCE**

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Edgar Filing: Sanofi - Form 6-K

Form 20-F  x

Form 40-F  o

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  o

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  o

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  o

No  x

If  Yes marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-

---

## Edgar Filing: Sanofi - Form 6-K

In September 2013, Sanofi issued the statements attached hereto as Exhibits 99.1 to 99.3 which are incorporated herein by reference.

### Exhibit List

<b>Exhibit No.</b>	<b>Description</b>
Exhibit 99.1	Press release dated September 12, 2013: Sanofi Provides Update on Lixisenatide New Drug Application in U.S.
Exhibit 99.2	Press release dated September 3, 2013: Menomune® Is the First Quadrivalent Meningococcal Vaccine Prequalified by the WHO
Exhibit 99.3	Press release dated August 30, 2013: European Commission Approves Genzyme's Once-Daily, Oral Multiple Sclerosis Treatment Aubagio® (teriflunomide)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: September 12, 2013

SANOFI

By	/S/ John Felitti
Name:	John Felitti
Title:	Associate Vice President, Corporate Law, Financial & Securities Law

**Exhibit Index**

<b>Exhibit No.</b>	<b>Description</b>
Exhibit 99.1	Press release dated September 12, 2013: Sanofi Provides Update on Lixisenatide New Drug Application in U.S.
Exhibit 99.2	Press release dated September 3, 2013: Menomune® Is the First Quadrivalent Meningococcal Vaccine Prequalified by the WHO
Exhibit 99.3	Press release dated August 30, 2013: European Commission Approves Genzyme's Once-Daily, Oral Multiple Sclerosis Treatment Aubagio® (teriflunomide)